Centauri Therapeutics attended ID Week 2022
Jennifer Schneider, CEO and Helen Bright, VP of Research & Development at Centauri Therapeutics, attended ID Week 2022, which took place from 19th to 23rd October in Washington DC. Helen presented an update on ABX01, our lead immune therapy programme targeting Gram-negative infections, during the “New Antimicrobials and ID Diagnostics…
Centauri Therapeutics Dr Mike Westby attended ESCMID/ASM Conference 2022
Dublin, 4th to 7th October 2022 – Dr Mike Westby, Centauri’s Chief Scientific Officer, presented at the 2022 ESCMID/ASM Conference on Drug Development, which aims to…
Centauri welcomes Dr Rinki Deb
Centauri is delighted to welcome Dr Rinki Deb to the team at Alderley Park. Rinki joins Centauri to take up the post of project manager…
Centauri welcomes Dr Hassan Al-Bewani
Centauri welcomes Dr Hassan Al-Bewani who joins the scientific team as senior immunologist. Hassan previously worked for the UK Health Security Agency and was awarded…
Centauri strengthens senior leadership team with three key appointments
Centauri is pleased to announce that Jennifer Schneider, Helen Bright and David Roblin have joined the senior leadership team. Please see this press release for…
Centauri welcomes Dr Aisha Baba Dikwa
Centauri welcomes Dr Aisha Baba Dikwa who joins the scientific team as senior microbiologist.
Centauri welcomes scientists to the team
Centauri is delighted to welcome Bailey Hairsine and Sana Mobeen to the scientific team. Reporting to Dr Helen Bright, Bailey and Sana will undertake in vitro research…
Centauri opens lab at Alderley Park
Centauri Therapeutics has taken a laboratory lease on Alderley Park and looks forward to research operations commencing shortly.
Centauri welcomes Dr Mike Westby, Chief Scientific Officer and Pamela Brown, Head of Chemistry
Following the recent investment announcement, Centauri is pleased to announce that Mike Westby and Pam Brown have joined Centauri Therapeutics. Mike is now Centauri’s Chief…